BACKGROUND & AIMS
To evaluate the effect of three-dimensional (3D) imaging device on polyp and adenoma detection during colonoscopy.
METHODS
In a single-blind, randomized controlled trial, participants aged 18-70 years who underwent diagnostic or screening colonoscopy were consecutively enrolled between August 2019 to May 2022. Each participant was randomized in 1:1 ratio to undergo either 2D-3D colonoscopy or 3D-2D colonoscopy through computer-generated random numbers. Primary outcome included polyp detection rate (PDR) and adenoma detection rate (ADR), defined as the proportion of individuals with at least 1 polyp or adenoma detected during colonoscopy. The primary analysis was intention-to-treat.
RESULTS
Of 1196 participants recruited, 571 in 2D-3D group and 583 in 3D-2D group were finally included after excluding those who met exclusion criteria. The PDR between 2D and 3D groups was separately 39.6% and 40.5% during phase 1 (OR=0.96, 95%CI: 0.76-1.22, P=0.801), whereas PDR was significantly higher in 3D group (27.7%) than that of 2D group (19.9%) during phase 2, with a 1.54-fold increase (1.17-2.02, P=0.002). Similarly, the ADR during phase 1 between 2D (24.7%) and 3D (23.8%) groups was not significant (OR=1.05, 0.80-1.37, P=0.788), while ADR was significantly higher in 3D group (13.8%) than that of 2D group (9.9%) during phase 2, with a 1.45-fold increase (1.01-2.08, P=0.041). Further subgroup analysis confirmed significantly higher PDR and ADR of 3D group during phase 2, particularly in midlevel and junior endoscopists.
CONCLUSION
The 3D imaging device could improve overall PDR and ADR during colonoscopy, particularly in midlevel and junior endoscopists. Trial number: ChiCTR1900025000.